A quantitative LC–MS/MS method for determining ipragliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, and its application to a pharmacokinetic study in rats

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice

Atsuo Tahara, Eiji Kurosaki, Masanori Yokono et al. · European Journal of Pharmacology · 2013 · 310 citations

Medicine, Endocrinology, Pharmacology +17

Discovery of Ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus

Masakazu Imamura, Keita Nakanishi, Takayuki Suzuki et al. · Bioorganic & Medicinal Chemistry · 2012 · 132 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo

Atsuo Tahara, Eiji Kurosaki, Masanori Yokono et al. · Naunyn-Schmiedeberg s Archives of Pharmacology · 2011 · 109 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +6

New features on the fragmentation and differentiation of <i>C</i> ‐glycosidic flavone isomers by positive electrospray ionization and triple quadrupole mass spectrometry

Beatriz Abad‐García, Sergio Garmón‐Lobato, Luis Á. Berrueta et al. · Rapid Communications in Mass Spectrometry · 2008 · 109 citations

Pharmacy, Biochemistry, Pharmaceutical Analysis +17

Validated LC–MS/MS Methods for The Determination of Dapagliflozin, A Sodium-Glucose Co-Transporter 2 Inhibitor in Normal and ZDF Rat Plasma

Anne‐Françoise Aubry, Huidong Gu, Reynald Magnier et al. · Bioanalysis · 2010 · 69 citations

Pharmacy, Pharmaceutical Analysis, Pharmacology +15